Leggett & Platt Reports 2Q 2026 Results

Leggett & Platt reported 2Q26 sales of $1.0B (-6% YoY) and EPS of $0.33 (-13% YoY), while adjusted EPS was $0.39 (+$0.09 YoY). Adjusted EBIT rose to $89M (+18% YoY) and adjusted EBIT margin improved to 8.9% (+180 bps), but EBIT fell to $80M (-11%) as reported results were pressured by lower earnings and non-recurring items. Management cited weak bedding demand (U.S. mattress units down low double digits) and soft housing/consumer-related markets, while noting HSR approval has cleared for its planned Somnigroup merger (close expected after Aug. 20 shareholder vote and remaining regulatory approvals). Net debt remains at 2.6x trailing 12-month adjusted EBITDA, with operating cash flow down to $46M (-$38M YoY), indicating near-term cash pressure despite margin improvement.

Analysis

This print is more useful as a read-through on end-demand than as a standalone equity catalyst. The quality of earnings is weak: headline margin improvement is being masked by nonrecurring mix/pricing and merger-related noise, while the underlying volume trend still points to a slow burn rather than a cyclical inflection. That matters because the business mix is concentrated enough that a few more quarters of mattress and residential weakness can overwhelm any cost program benefits.

The bigger second-order effect is across the bedding and home-furnishings supply chain: OEMs and retailers are likely to keep de-stocking, which pressures component suppliers, lowers replenishment orders, and extends the downcycle for wire/spring, foam, and adjacent fabricated-metal vendors. Competitors with higher exposure to mattress units than this name will likely feel worse margin compression because they have less diversification and less pricing power in a market where retail traffic is soft. On the auto side, the sub-market underperformance is a warning that component suppliers are still fighting for share rather than riding a production upcycle.

From a risk perspective, the key catalyst is not the quarter but the merger clock. If shareholder approval or remaining regulatory steps slip, the stock reverts to a deteriorating standalone credit/equity story with limited organic growth and weakening cash generation; if the deal closes on schedule, equity upside is mostly capped by the exchange ratio and the trade becomes a volatility/spread problem, not a fundamentals story. The main falsifier is a meaningful rebound in mattress units or a faster housing turn than the current channel inventory data imply, which would take several months to show up and would need to be visible in the next two quarters, not this one.

Key Decisions for Investors

• Hold LEG only in a hedged merger-arbitrage structure; pair long LEG against short SGI into the Aug. 20 vote, but only if the spread widens materially on any regulatory or shareholder-noise headline.
• Do not initiate an outright long LEG position here: the reported margin upside is not durable, and the downside is only partially protected by the deal until closing conditions are fully cleared.
• Use any rally in mattress-linked names to fade the move: short TPX or SNBR on evidence that low-double-digit unit declines are persisting, with a 1-3 month horizon and the thesis invalidated by channel fill and positive unit comps.
• For event-driven accounts, buy short-dated downside protection on SGI only if the market starts to price in closing slippage; otherwise the cleaner trade is the LEG/SGI spread, not a directional SGI short.
• Set a watch item on U.S. mattress units, residential orders, and LEG cash conversion in the next 1-2 quarters; if organic sales stabilize but working capital keeps absorbing cash, the standalone equity and bond thesis both improve less than the reported margin suggests.